BBK Worldwide Blog

Pharma15 Live!

Facilitating the Journey from Patient to Study Participant

The Impact of Dynamic Referral Processing

Matt Kibby and Aaron Fleishman return to the Pharma15 Live! stage to discuss BBK's dynamic referral processing service and how it improves and accelerates the patient enrollment process. 

"Our process benefits both patients and sites alike. It unburdens the study staff, creating a better experience for them, while also ensuring patients are responded to more quickly and with better care so their journey is a positive one."

-Matt Kibby, President, Chief Strategy Officer, BBK Worldwide

Blueprint for Success: Proven Strategies for Patient Engagement

Download our blueprint for patient engagement and get a compilation of ideas and proven strategies to help you and your clinical trial team create a successful patient engagement program.

Words Matter: The Hybrid Lexicon

In a time of confusing terminology, one thing is clear: what the industry used to consider exceptional is now considered essential.

Hybrid. Decentralized. Remote. Digital. Virtual. Companies use these terms interchangeably. There is inconsistency, over-hyping, over-promising, confusion and a notable lack of substance. To be honest, it’s a bit like the Wild West out there.

New survey findings reveal the importance of offering patients choice when it comes to improving clinical trial diversity, access, and engagement.

Patients want options, or choice, when it comes to clinical trial participation. New data from a recent Study Voices survey reveals the impact choice can have on participation. The findings empower clinical trial sponsors to shift from traditional clinical trial enrollment models to hybrid enrollment models.

DOWNLOAD NOW

A Diversified Outreach Strategy
Is Key to Clinical Trial Inclusivity

New Infographic Available for Download

Many clinical trial sponsors are seeking ways to enable hybrid study designs with ease and confidence. Our new infographic follows the patient's journey from consideration to enrollment to engagement throughout the study life cycle, with information to help sponsors create a more diverse and inclusive participation environment.

We are all hoping that 2022 will be a better year for the world, one where the impact of the pandemic truly begins to subside for everyone around the globe. That said, it is a basic truth that every challenge presents some opportunity, and the impact of COVID-19 on the clinical research and development industry has been no exception.

We are very excited to kick off the new year with the announcement that we have been acquired by Publicis Health, the healthcare communications leader that transforms healthcare marketing and communications into healthcare engagement.

Together, we share a commitment to the clinical trial experience and to enhancing understanding and access for all, and we look forward to joining the Publicis Health network. Our mission remains unchanged, as does our commitment to supporting you in advancing your clinical R&D efforts.

The clinical trial landscape saw a lot of changes in 2021, from decentralized clinical trial adoption to a greater emphasis on diversity and inclusion. But what’s in store for 2022? We asked our industry experts to weigh in with their predictions.

New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer.

When we developed our latest Study Voices survey, we expected to see large gaps in attitudes and experiences among healthcare consumers and clinical trial participants based on factors such as age, race, ethnicity, gender, and income – but that wasn’t the case.

Catch Up on Our Content for Clinical Trial Sponsors

Now is the perfect time to catch up on our most popular content of 2021!

Featuring insights from industry thought leaders, our content provides clinical trial sponsors with knowledge and guidance to help navigate today’s challenging clinical trial enrollment and engagement landscape.